- Connect Biopharma (NASDAQ: CNTB) to present four posters at ATS 2025 International Conference.
- Focus on rademikibart's efficacy in treating asthma and COPD.
- Phase 2 trials for rademikibart to begin in Q2 2025.
Connect Biopharma Holdings Limited (NASDAQ: CNTB), a clinical-stage biopharmaceutical company, announced its participation at the upcoming American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The company plans to present four posters focused on their drug candidate, rademikibart, developed for the treatment of moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD).
Rademikibart has been shown to rapidly improve lung function in asthma patients and demonstrates efficacy in COPD-like patient groups. Key presentations will cover topics such as the drug's effect on blood eosinophil counts and structural properties of its IL-4Rα complex.
The company aims to initiate parallel Phase 2 trials by the second quarter of 2025, continuing their development efforts in targeting acute exacerbations in asthma and COPD, areas with significant unmet medical needs. These findings indicate a promising advancement in the clinical development of rademikibart, potentially benefiting approximately 1 million asthma and 1.3 million COPD patients experiencing acute exacerbations annually in the U.S.
Prominent presenters at the conference include Dr. Michael Wechsler and Dr. Raúl Collazo, with sessions focusing on clinical studies and treatment modalities in inflammatory lung diseases. Connect Biopharma remains dedicated to transforming acute and chronic care for asthma and COPD patients.
